pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
234
stories
3h
Sionna says good-bye to 46% of staffers, including exec
biospace
3h
STAT+: Obesity drugmakers are testing in kids as young as 6
stat
4h
STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more
stat
7h
STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
stat
9h
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
1d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
1d
STAT+: GSK touts lung cancer data from two drugs
stat
1d
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
stat
1d
Scholar Rock SMA drug approved by FDA
biopharma dive
1d
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
1d
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
1d
STAT+: Definium’s LSD therapy eased anxiety in second large trial
stat
1d
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
stat
2d
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg
fiercebiotech
3d
Setbacks for Novartis; Anthropic looks for a dealmaker; and more
endpoints
3d
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
stat
3d
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
stat
4d
U.S. officials declare an end to record-setting cyclospora outbreak, but its origin is still unknown
stat
4d
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
4d
STAT+: Up and down the ladder: The latest comings and goings
stat
4d
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
stat
4d
STAT+: Cancer drug shortages keep disrupting patient care
stat
4d
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
4d
Novartis drags peers down with triple asset stumble
biospace
4d
Novartis drags peers down with triple asset failure
biospace
4d
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
stat
4d
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
stat
4d
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
4d
Singapore launches biotech-focused Boston hub to build on 'centuries-old bond'
fiercebiotech
4d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
← prev
page 1 of 8
next →
